Conatus Pharma

CNAT NASDAQ
0.3229
+0.0045
+1.41%
After Hours: 0.3240 +0.0011 +0.34% 17:56 07/17 EDT
Open
0.3198
Prev Close
0.3184
High
0.3400
Low
0.2980
Volume
807.12K
Avg Vol (3M)
971.42K
52 Week High
6.74
52 Week Low
0.2500
% Turnover
2.43%
Market Cap
10.71M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Conatus Pharma CNAT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
MORE >

Recently

Name
Price
%Change